COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00388388
Recruitment Status : Terminated (Few subjects recruited, sponsor withdrew support.)
First Posted : October 16, 2006
Last Update Posted : May 19, 2015
Merck Frosst Canada Ltd.
Information provided by (Responsible Party):
Ernesto L. Schiffrin, Sir Mortimer B. Davis - Jewish General Hospital

Brief Summary:
This randomized, double-blind, parallel group, two-centre pilot study will test the hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis of pre-hypertension and pre-diabetes will have regression or reduced progression of hypertension-associated changes in their resistance arteries if their blood pressure is controlled for 6 months with losartan, whereas similar subjects whose blood pressure is equally well controlled using hydrochlorothiazide will have significantly less improvement of the changes in their resistance arteries.

Condition or disease Intervention/treatment Phase
Pre-hypertension Pre-diabetes Drug: losartan, hydrochlorothiazide Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects
Study Start Date : March 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes

Arm Intervention/treatment
Experimental: 1
Losartan treatment
Drug: losartan, hydrochlorothiazide
Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Other Name: Cozaar, Apo-hydro

Active Comparator: 2
Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
Drug: losartan, hydrochlorothiazide
Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Other Name: Cozaar, Apo-hydro

Primary Outcome Measures :
  1. Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prehypertensive prediabetic subjects (25-70 years old) defined as otherwise normal subjects with a mean SiSBP of 120-139 mmHg and fasting blood glucose of 6.1-6.9 mmol/L or impaired glucose tolerance on oral glucose tolerance test (OGTT) at screening and after two weeks of placebo therapy (Week -2)

Exclusion Criteria:

  • Hypertension or clinically significant renal disease
  • Cerebrovascular accident within the past year, or current transient ischemic attacks
  • Myocardial infarction within the past year; percutaneous coronary angioplasty or coronary artery bypass surgery within last 6 months
  • Clinically significant AV conduction disturbances and/or arrhythmias (e.g. second- or third-degree AV block; sick-sinus syndrome or clinically significant bradycardia- resting heart rate < 45 beats/minute), tachyarrhythmias; clinically significant arrhythmias, presence of accessory bypass tract (e.g. Wolff-Parkinson-White syndrome)
  • Angina pectoris
  • Current or prior history of heart failure or known left ventricular ejection fraction <40%
  • History of unexplained syncope or known syncopal disorder (e.g., Stokes-Adams Syndrome)
  • Known history of hemodynamically significant obstructive valvular disease or hypertrophic cardiomyopathy
  • Use of agents that may cause alteration of blood pressure is prohibited. This includes nitrates, or alpha or beta-blockers. Calcium channel blockers are allowed as second line therapy if hypertension develops during the study Major psychotropic agents and antidepressants are not permitted
  • Cimetidine is not permitted (famotidine and ranitidine and proton pump inhibitors are allowed).
  • NSAIDs are permitted if taken on a stable regimen. Aspirin in small doses (< 1 g/day) as cardioprotective agent and acetaminophen are permitted
  • Oral or inhaled steroids, ACTH, immunosuppressants or lithium are not allowed
  • Serum creatinine concentration >200 μmol/L (adjusted for age and weight)
  • Urine dipstick or microscopic findings suggestive of significant renal or other disease.
  • Hematuria should be evaluated, the etiology established/documented, and treatment rendered as appropriate prior to entry
  • Off-treatment serum potassium concentration >5.5 mmol/L or <3.5 mmol/L
  • AST (SGOT) or ALT (SGPT) >2 x normal upper limit
  • Clinically significant laboratory values outside of the established normal range including but not limited to the following parameters: hemoglobin, platelet count or white blood cell count
  • Known hypersensitivity or contraindication to losartan or thiazide diuretics
  • History of clinically important malabsorption or gastrointestinal resection
  • Current urinary tract infection
  • Smoking 10 cigarettes or more.
  • Pregnancy or lactating females. Females of childbearing age who are not surgically sterilized and are using effective contraception may enter only if an exclusionary pregnancy test is done within 72 hours of the first double-blind dose of test agent. Pregnancy tests will then be done monthly throughout the study.
  • Vasculitis or vasculopathy: collagen-vascular diseases, chronic hepatitis B antigenemia, circulating immune complexes, complement disorders, amyloidosis, scleroderma, etc. Neoplasms, Acquired Immunodeficiency Syndrome (AIDS), or HIV positive
  • Bleeding or platelet disorder
  • Known absence of one kidney
  • Subjects abusing or who within past two years abused alcohol or other drug substances
  • Mentally or legally incapacitated subjects
  • Subjects who have participated in another investigational drug trial, including those using marketed drugs (i.e. patient has signed a consent form), within the 28 days prior to start of placebo therapy
  • Subjects who, in the opinion of the investigator, will not cooperate fully, keep appointments or are unreliable
  • Inability or unwillingness to sign the Patient Consent Form
  • Phase V of Korotkoff sounds cannot be detected

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00388388

Layout table for location information
Canada, Quebec
Cardiovascular Prevention Centre, Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.
Layout table for investigator information
Principal Investigator: Ernesto L. Schiffrin, MD, PhD Physician-Chief, SMBD - Jewish General Hospital & Professor of Medicine, McGill University
Additional Information:
Layout table for additonal information
Responsible Party: Ernesto L. Schiffrin, Physician-in-Chief, Sir Mortimer B. Davis - Jewish General Hospital Identifier: NCT00388388    
Other Study ID Numbers: CPC030
First Posted: October 16, 2006    Key Record Dates
Last Update Posted: May 19, 2015
Last Verified: May 2015
Keywords provided by Ernesto L. Schiffrin, Sir Mortimer B. Davis - Jewish General Hospital:
Resistance arteries
angiotensin receptor blocker
thiazide diuretic
Additional relevant MeSH terms:
Layout table for MeSH terms
Prediabetic State
Vascular Diseases
Cardiovascular Diseases
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators